In this episode of the Oncology Insights Podcast, host Dr. Petros Grivas is joined by Dr. Stanley Riddell, one of the world's leading pioneers of cancer immunotherapy and a longtime physician-scientist at Fred Hutch. Dr. Riddell's career traces the remarkable evolution of immunotherapy, from the early days of bone marrow transplantation to the development of genetically engineered T-cell therapies that are transforming cancer care today.

Main Topics:

1. Dr. Riddell's career path and contributions to immunotherapy

2. Development and clinical success of CAR T cell therapy

3. Challenges of translating immunotherapy from lab to clinic

4. Future of cancer treatment and possibilities for solid tumors

5. Collaboration between academia, industry, and global health equity

6. The importance of perseverance and impactful research

Timestamps:

1. 00:00 - Introduction to Dr. Stanley Riddell and his contributions to immunotherapy

2. 02:00 - Early career: Stem cell transplant and immunology breakthroughs

3. 05:00 - Overcoming infectious complications in transplant patients

4. 08:00 - Development of CMV-specific T cells and initial cancer applications

5. 11:00 - The birth and growth of CAR T cell therapy at Fred Hutch

6. 12:50 - Clinical successes and ongoing challenges in CAR T treatments

7. 15:00 - Industry collaborations and commercialization efforts

8. 16:00 - Implementing CAR T therapies in community settings and future innovations

9. 18:00 - Addressing healthcare disparities globally

10. 20:00 - The infrastructure at Fred Hutch supporting cutting-edge research

11. 23:00 - The promising future of biomedical science and immunology

12. 25:00 - Role of funding and federal support in sustaining innovation

13. 26:00 - Potential of immunotherapy in solid tumors and personalized medicine

14. 28:00 - Final thoughts: hope for curing more patients and improving quality of life

Resources & Links:

Stan Riddell Faculty Bio: https://www.fredhutch.org/en/faculty-lab-directory/riddell-stanley.html

In this episode of the Oncology Insights Podcast, host Petros Grivas, MD, PhD, FASCO, speaks with Lei Deng, MD, a thoracic oncologist at Fred Hutch Cancer Center and the University of Washington, about advances in lung cancer research and patient care.

Deng discusses how precision medicine, immunotherapy and rapid molecular testing are improving outcomes for patients with lung cancer. The conversation also highlights the importance of early detection, team-based care and delivering treatment that reflects patients' values and priorities.

Key topics include:

1. Deng's path into lung cancer research and thoracic oncology

2. Advances in targeted therapies and precision oncology for key lung cancer mutations

3. The role of biomarkers and immunotherapy in treatment decision-making

4. Innovative clinical trials at Fred Hutch and the University of Washington

5. Early detection, rapid molecular testing and multidisciplinary care

6. Patient-centered care, including communication, emotional support and shared decision-making

Timestamps:

1. 00:07 - Introduction to Dr. Lei Deng and her work in thoracic oncology

2. 01:21 - Dr. Deng's pathway into lung cancer research and joining Fred Hutch

3. 02:57 - Exploring current research focus areas and promising trials in precision medicine

4. 07:35 - The significance of MTAP loss and targeted therapy development

5. 10:20 - Rapid access to care and multidisciplinary team collaboration

6. 14:44 - Molecular testing timing and its role in personalized lung cancer treatment

7. 16:46 - Trends in young patients with lung cancer and multifactorial etiology

8. 18:25 - Impact and future of lung cancer screening programs

9. 22:54 - Genetic predisposition and familial risk assessments

10. 24:28 - The importance of patient communication and listening to patient voices

Resources & Links:

Fred Hutch Cancer Center: fredhutch.org

Lei Deng, MD, provider profile: https://www.fredhutch.org/en/provider-directory/lei-deng.html

Petros Grivas, MD, PhD, FASCO, provider profile: https://www.fredhutch.org/en/provider-directory/petros-grivas.html

Join us as we explore the latest advancements in immunotherapy at Fred Hutch, including CAR T-cell therapy, novel agents, strategies to expand access, and collaboration between research and community care. Dr. Mazyar Shadman, Medical Director of Cellular Immunotherapy and Deputy Chief Medical Officer at Fred Hutch, shares insights on the future of cancer treatment and the importance of teamwork in oncology.

Chapters:

00:00 Intro

00:48 The Journey to Fred Hutch and Immunotherapy Innovations

07:24 Building Bridges: Community and Access to Care

14:25 Advancements in Clinical Trials and Future Directions

20:18 Vision for the Future: Leadership and Teamwork

Links:

Mazyar Shadman: Provider Profile, X

Petros Grivas: Provider profile, X

Subscribe to Oncology Insights

In this episode, Dr. Christina Baik shares her journey to Fred Hutch, her research on lung cancer, and the importance of patient-centered care and interdisciplinary collaboration in advancing cancer treatment.

Chapters

Guest Links:

Dr. Baik's Provider Profile: https://www.fredhutch.org/en/provider-directory/christina-s-baik.html

Dr. Grivas' Provider Profile: https://www.fredhutch.org/en/provider-directory/petros-grivas.html

In this episode, Dr. Rosa Nadal shares her journey from Spain to the U.S., her work in cellular immunotherapy for genitourinary cancers, and the innovative programs at Fred Hutch. Discover insights into personalized cancer treatments, multidisciplinary care, and future directions in immunotherapy.

Key Topics

• Dr. Nadal's international journey and training in the U.S.

• Development of cellular immunotherapy programs for solid tumors

• Multidisciplinary approach to bladder and prostate cancer care

• Translational research in immunotherapeutics and resistance mechanisms

• Clinical trial access and personalized treatment strategies

Chapters

00:00 Introduction to Dr. Rosa Nadal

01:14 Dr. Nadal's Journey from Spain to Seattle

04:30 Vision for Cellular Immunotherapy Program

07:58 Translational Research and Clinical Trials

10:57 Improving Patient Access to Care

14:23 Multidisciplinary Care at Fred Hutch

17:54 Optimism for the Future of Cancer Treatment

Links

Fred Hutch Cancer Center - https://www.fredhutch.org

Dr. Rosa Nadal's Profile - https://www.fredhutch.org/en/people/profile/rosa-nadal.html

CAR-T Cell Therapy Trials at Fred Hutch - https://www.fredhutch.org/en/clinical-trials/cancer/immunotherapy.html

In this episode of Meet the Greek, Dr. Tom Lynch, president and director of Fred Hutch Cancer Center, shares his journey in oncology, emphasizing the importance of patient care, clinical trials and the impact of philanthropy on cancer research. He discusses the evolution of lung cancer treatment, the challenges in research funding, and the significance of precision oncology and multidisciplinary care. Dr. Lynch also offers insights into effective leadership in healthcare and reflects on his career experiences, highlighting the importance of the journey in medicine.

Takeaways

• The most impactful breakthroughs in medicine begin with individual patient stories.
• Cross-sector experience creates a mental model for solving complex health problems.
• Breakthroughs in precision medicine are as much about integrating diagnostics as they are about developing treatments.
• The true power of multidisciplinary teams lies in their early, coordinated engagement in patient care.
• Sustaining research momentum demands innovative funding models and community support.

In this episode of Meet the Greek, Dr. Heather Parsons discusses her journey in oncology, focusing on breast cancer. She highlights the importance of circulating tumor DNA in detecting cancer and guiding treatment decisions. The conversation also covers exciting clinical trials, the significance of multidisciplinary care, and the role of genetic testing in patient management. Dr. Parsons emphasizes the need for timely access to care and collaboration with community oncologists to improve patient outcomes. Looking ahead, she shares her vision for the future of breast cancer care at Fred Hutch Cancer Center.

Takeaways

• Circulating tumor DNA can reveal cancer changes through a simple blood test.
• The technology surrounding circulating tumor DNA is rapidly evolving.
• Refining patient groups for therapy can enhance clinical trial efficiency.
• A recent study found 10% of patients had detectable DNA in their blood.
• Proactive symptom management is crucial in cancer care.
• Genetic testing is vital for personalized cancer treatment.
• Collaboration with community oncologists is essential for comprehensive care.
• The future of breast cancer care is promising with ongoing research and innovation.

In this episode of Meet the Greek, Dr. Petros Grivas and Dr. David Zhen discuss the latest advancements in gastrointestinal cancers, focusing on gastroesophageal and neuroendocrine cancers. They explore the exciting new therapies and clinical trials that are changing the landscape of treatment, the importance of collaboration with community oncology, and the role of genetic factors in cancer predisposition. The conversation also highlights the significance of a multidisciplinary approach in patient care and the growing need for survivorship programs as more patients live longer after treatment. Looking ahead, they discuss future directions in GI oncology, including the potential for de-escalation of therapies and the integration of novel treatments.

Takeaways

• There has been significant momentum in GI cancer treatments recently.
• New therapies include immunotherapies and CAR-T therapies.
• Collaboration with community oncology is essential for patient care.
• Genetic predisposition plays a crucial role in cancer management.
• Young onset colorectal cancer is on the rise.
• Multidisciplinary teams are vital for effective treatment.
• Survivorship programs are becoming increasingly important.
• Clinical trials are essential for advancing cancer treatment.
• De-escalation of therapies may improve patient outcomes.
• The future of GI oncology looks promising with novel therapies.